Denali(DNLI) - 2025 Q4 - Annual Results

Exhibit 99.1 Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights SOUTH SAN FRANCISCO, Calif., – February 26, 2026 – Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights. Fourth Quarter 2025 and Recent Program Updates CLINICAL PROGRAMS Tividenofusp alfa (DNL310; ETV:IDS) for Hunter syndrome (mucopolysaccharidosis type II [MPS II]) Denali has es ...